EC Number   |
Title |
Organism |
|---|
   2.1.1.67 | A 6-Thioguanine Nucleotide Threshold Level of 400 pmol/8 x 10(8) Erythrocytes Predicts Azathioprine Refractoriness in Patients With Inflammatory Bowel Disease and Normal TPMT Activity |
Homo sapiens |
| 2.1.1.67 | A novel gene delivery system for stable transfection of thiopurine-S-methyltransferase gene in versatile cell types |
Homo sapiens |
| 2.1.1.67 | A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase |
Homo sapiens |
| 2.1.1.67 | Allele frequency of thiopurine methyltransferase and inosine triphosphate pyrophosphatase gene polymorphisms in Korean patients with inflammatory bowel diseases |
Homo sapiens |
| 2.1.1.67 | An audit of thiopurine methyltransferase genotyping and phenotyping before intended azathioprine treatment for dermatological conditions |
Homo sapiens |
| 2.1.1.67 | Analytical and clinical validation of an LC-MS/MS method to measure thiopurine S-methyltransferase activity by quantifying d3-6-MMP |
Homo sapiens |
| 2.1.1.67 | Assessment of thiopurine methyltransferase enzyme activity is superior to genotype in predicting myelosuppression following azathioprine therapy in patients with inflammatory bowel disease |
Homo sapiens |
| 2.1.1.67 | Avoiding adverse drug reactions by pharmacogenetic testing: a systematic review of the economic evidence in the case of TPMT and AZA-induced side effects |
Homo sapiens |
| 2.1.1.67 | Azathioprine and diffuse alveolar haemorrhage: the pharmacogenetics of thiopurine methyltransferase |
Homo sapiens |
| 2.1.1.67 | Azathioprine-associated acute myeloid leukemia in a patient with Crohns disease and thiopurine S-methyltransferase deficiency |
Homo sapiens |
